X4 Pharmaceuticals (XFOR) Receivables (2019 - 2025)
X4 Pharmaceuticals (XFOR) reported Receivables of $573000.0 for Q4 2025, down 66.49% on a YoY basis from $1.7 million in Q4 2024, and down 64.32% quarter-over-quarter from $1.6 million in Q3 2025.
X4 Pharmaceuticals (XFOR) Receivables (2019 - 2025) Analysis & Trends
X4 Pharmaceuticals has reported Receivables for 5 years, with the latest figure at $573000.0 in Q4 2025.
- For the quarter ending Q4 2025, Receivables fell 66.49% year-over-year to $573000.0; the trailing twelve-month figure through Dec 2025 stood at $573000.0 (down 66.49% YoY), and the FY2025 full-year result was $573000.0, down 66.49% from the prior year.
- Receivables for Q4 2025 stood at $573000.0, down from $1.6 million in the prior quarter.
- The five-year high for Receivables was $1.9 million in Q2 2025, with the low at $562000.0 in Q4 2023.
- Historically, Receivables has averaged $1.2 million across 3 years, with a median of $1.1 million in 2024.
- Annual changes were most pronounced in 2024 — Receivables jumped 204.27% — and 2025, when it sank 66.49%.
- X4 Pharmaceuticals' Receivables stood at $562000.0 in 2023, then jumped by 204.27% to $1.7 million in 2024, then plunged by 66.49% to $573000.0 in 2025.
- The last three Receivables figures came in at $573000.0 (Q4 2025), $1.6 million (Q3 2025), and $1.9 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 13.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 2.00 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | X4 Pharmaceuticals | 156.06 Mn | 156.06 Mn | 2.20 Mn | 573,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 573,000.00 |
| Sep 30, 2025 | 1.61 Mn |
| Jun 30, 2025 | 1.87 Mn |
| Mar 31, 2025 | 1.17 Mn |
| Dec 31, 2024 | 1.71 Mn |
| Sep 30, 2024 | 1.07 Mn |
| Jun 30, 2024 | 854,000.00 |
| Dec 31, 2023 | 562,000.00 |
| Sep 30, 2020 | 3.63 Mn |
| Jun 30, 2020 | 3.51 Mn |
| Mar 31, 2020 | 3.42 Mn |
| Dec 31, 2019 | 2.00 Mn |